UCB
UCB SA, established in 1928, is a Belgium-based biopharmaceutical company that develops and markets therapies for neurology and immunology diseases. Its primary products include Cimzia for inflammatory diseases, Vimpat and Briviact for epilepsy, Neupro for Parkinson's disease and restless legs syndrome, and Nayzilam for seizure clusters. Additionally, UCB offers treatments for allergies, memory problems, narcolepsy, and osteoporosis. The company is also involved in developing novel therapies for conditions like myasthenia gravis, drug-resistant epilepsy, and systemic lupus erythematosus. UCB engages in research and development activities in neurology, immunology, and other areas, and has collaboration agreements with several pharmaceutical companies.
Neurava
Seed Round in 2024
Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.
Ceribell, Inc. is a medical technology company that designs and manufactures devices for electroencephalography (EEG) data acquisition and interpretation, aimed at improving the diagnosis and management of neurological conditions. Its flagship product, the Ceribell EEG System, includes a flexible EEG Headband that accommodates various hair types and head sizes, alongside a portable EEG Recorder that ensures clinical-quality data and on-device display. The system is designed to be set up by any healthcare provider within six minutes, making EEG testing more accessible and efficient. Notably, it features a unique function that converts brainwaves into sound, allowing for quicker detection of seizures without the need for specialized technicians. This innovation facilitates earlier diagnosis and targeted treatment for patients, particularly for non-convulsive seizures, thereby reducing the risk of complications and improving overall patient outcomes. Established in 2014 and based in Mountain View, California, Ceribell is committed to enhancing care in hospital ICUs, inpatient units, and emergency departments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.